Navigation Links
A Product and Pipeline Analysis of the Human Plasma-derived Therapeutics Market
Date:12/15/2015

NEW YORK, Dec. 15, 2015 /PRNewswire/ -- The global human plasma-derived therapeutics market is expected to experience a surge in demand due to an increase in the awareness of diseases and therapeutic options. The plasma-derived therapeutics market is segmented into albumin, immunoglobulins, coagulation factors, and other haemotologicals. The segments are discussed with supporting information on clinical trial timelines and results and historical and projected launch timelines. The report also focuses on the competitive landscape of both marketed and pipeline products and provides the market drivers and challenges. Plasma-derived therapeutics market

Executive Summary
•The global human plasma-derived therapeutics market, worth $xxbillion in 2015, is set to grow at a CAGR of xx% to reach $xx billion by 2021.
•Rise in the global ageing population, increased awareness about the potential of plasma-derived therapeutics, early diagnosis of diseases, and the growing popularity of plasma-derived products in the emerging economies are the key factors driving the growth.
•However, there are significant challenges in handling the strict regulations of different countries with respect to selection of donors, plasma screening process, and fractionation process.
•In 2015, CSL Behring, Baxter, Grifols, Kedrion, and Octapharma were the top xx competitors; however, companies such as Sanquin are gaining ground quickly.
•In the past, there have been significant consolidations such as the $xx billion acquisition of Talecris in 2011 by Grifols. The market is further expected to witness big industry consolidations for economies of scale and market access.
•The IVIG segment will continue to be the market driver because of the heavy R&D investment in biologics development by market leaders such as Grifols, Octapharma, and CSL Behring.
•A recent pre-clinical research study at Stanford University showed that blood plasma derived from young mice and injected into older mice rejuvenated the health and memory of the older mice. Several other studies like this one may open up new indications such as Alzheimer's disease and other age-related diseases for the human plasma-derived therapeutics market in the coming years.

Methodology and Scope
•This research service focuses on human plasma-derived prescription drugs used for the treatment of liver and kidney diseases, burns, surgeries, cardiopulmonary bypass, hypovolemia, albumin deficiency (hypoalbuminemia), acute nephrosis, ovarian hyperstimulation syndrome, neonatal hyperbilirubinemia, acute respiratory distress syndrome (ARDS), hereditary angioedema, Von Willebrand disease (vWD), factor VII / X / XI / XIII deficiencies, haemophilia A and B, fibrinogen deficiency, hereditary anti-thrombin deficiency, surgical bleeding, chronic inflammatory demyelinating polyneuropathy (CIDP), idiopathic thrombocytopenic purpura (ITP), rabies, tetanus, hepatitis A and B, chickenpox, primary immunodeficiency (PI), x-linked agammaglobulinemia, severe combined immunodeficiency, and Wiskott–Aldrich syndrome.
•This study does not include recombinant products and bovine-plasma products. Only human plasma-derived products have been used in market segmentation, market size, and forecasting.
•A product and pipeline assessment is provided for marketed and investigational plasma-derived products. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, projected launch timelines, and epidemiology.
•The information contained in this research service was derived from published sources including disease organisation websites; public health organisation websites; company publications including annual reports, SEC filings, and press releases; government public sources; pipeline databases; and published articles in scientific journals.

Read the full report: http://www.reportlinker.com/p03471853-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. X-Change Corporation Launches Upgraded Version of Phytiva Website, As Company Targets Distribution of Phytiva Product Line in United States and Worldwide, Extracts and New Products in Europe
2. Novelos Therapeutics Provides Product Pipeline Update
3. iHealth Lab adds new products and partners to mobile personal healthcare offering
4. Worldwide Orthopaedic Product Sales Reached $43.1 Billion in 2012, States ORTHOWORLDs Newly-released Orthopaedic Industry Report
5. CCS Medical Announces Enhanced Product Formulary
6. Drug Self-Administration to 2018 - Drug Products, Indications, Markets and Forecasts
7. Finesse Solutions Launches Next Generation G3Lab Universal SmartControllers to Enhance Productivity in Bench Scale Cell Culture and Fermentation
8. New Air Products Microsite Features Advanced Liquid Nitrogen Solutions for the Chemical, Pharmaceutical, and Life Science Industries
9. Affiliate Retailer of Health and Wellness Products Announces New Online Store at YouNeedIt.biz
10. Waters Introduces the SYNAPT G2-Si to Its Mass Spectrometer Product Line
11. SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2020)... ... August 31, 2020 , ... If you live in New York City you will always pay ... sense, it’s the law of supply and demand, but are plastic surgeons in New York ... percentage of their patients that make the four-hour trip to have expert aesthetic treatments by ...
(Date:8/28/2020)... ... August 28, 2020 , ... Cano Health, LLC, a ... Florida and San Antonio is happy to announce that it has selected Tejano ... this capacity he will serve as community advisor, advertising talent, and creative consultant ...
(Date:8/27/2020)... ... August 27, 2020 , ... InfoMC, ... the successful completion of their 2020 System and Organizational Controls (SOC) 1® Type ... assessment and MARS-E compliance assessment. These achievements reflect their long-standing commitment to privacy, ...
Breaking Medicine Technology:
(Date:8/31/2020)... ... August 31, 2020 , ... ... opportunities through high-quality, career-relevant, and affordable online education – is proud to announce ... , Among the first of its kind in the nation, the 60-credit hour ...
(Date:8/31/2020)... ... August 31, 2020 , ... A Cure for Covid-19 “PTS” with Mediation & Hypnosis ... planet are in a state of panic, experiencing deep anxiety, immense stress, and right now ... solution is timely when most people on the planet are experiencing a great degree of ...
(Date:8/31/2020)... NEW HAVEN, Conn. (PRWEB) , ... August 31, ... ... a medical device intended to improve outcomes for patients with advanced heart failure, ... Innovation Research (SBIR) grant in the amount of $555,358 from the National Heart, ...
(Date:8/28/2020)... ... 28, 2020 , ... WHAT , Hespiro™ is a new ... conditions, including COVID-19, while reducing the need for scarce mechanical ventilators. It not ... and scrubs it free of carbon dioxide in a completely closed “rebreather” system, ...
(Date:8/28/2020)... ... August 28, 2020 , ... Integrated Viral Protection (IVP Air) today ... to deploy its breakthrough Mobile Biodefense Indoor Air Protection System that is the first ... plans to fully reopen equipped with the filtration system on September 8th. , ...
Breaking Medicine News(10 mins):